Cargando…
A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
BACKGROUND: The diversity and plasticity behind ER+/PR−/HER2− breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. METHODS: Based on the immune-related gen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454077/ https://www.ncbi.nlm.nih.gov/pubmed/34544424 http://dx.doi.org/10.1186/s12967-021-03076-x |
_version_ | 1784570414456897536 |
---|---|
author | Xie, Peiling An, Rui Yu, Shibo He, Jianjun Zhang, Huimin |
author_facet | Xie, Peiling An, Rui Yu, Shibo He, Jianjun Zhang, Huimin |
author_sort | Xie, Peiling |
collection | PubMed |
description | BACKGROUND: The diversity and plasticity behind ER+/PR−/HER2− breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. METHODS: Based on the immune-related gene expression profiles of 411 ER+/PR−/HER2− breast cancers in the METABRIC cohort, we used consensus clustering to identify heterogeneous immune subtypes and assessed their reproducibility in an independent meta-cohort including 135 patients collected from GEO database. We further analyzed the differences of cellular and molecular characteristics, and potential immune escape mechanism among immune subtypes. In addition, we constructed a transcriptional trajectory to visualize the distribution of individual patient. RESULTS: Our analysis identified and validated five reproducible immune subtypes with distinct cellular and molecular characteristics, potential immune escape mechanisms, genomic drivers, as well as clinical outcomes. An immune-cold subtype, with the least amount of lymphocyte infiltration, had a poorer prognosis. By contrast, an immune-hot subtype, which demonstrated the highest infiltration of CD8+ T cells, DCs and NK cells, and elevated IFN-γ response, had a comparatively favorable prognosis. Other subtypes showed more diverse gene expression and immune infiltration patterns with distinct clinical outcomes. Finally, our analysis revealed a complex immune landscape consisting of both discrete cluster and continuous spectrum. CONCLUSION: Overall, this study revealed five heterogeneous immune subtypes among ER+/PR–/HER2− breast cancer, also provided important implications for clinical translations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-03076-x. |
format | Online Article Text |
id | pubmed-8454077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84540772021-09-21 A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape Xie, Peiling An, Rui Yu, Shibo He, Jianjun Zhang, Huimin J Transl Med Research BACKGROUND: The diversity and plasticity behind ER+/PR−/HER2− breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. METHODS: Based on the immune-related gene expression profiles of 411 ER+/PR−/HER2− breast cancers in the METABRIC cohort, we used consensus clustering to identify heterogeneous immune subtypes and assessed their reproducibility in an independent meta-cohort including 135 patients collected from GEO database. We further analyzed the differences of cellular and molecular characteristics, and potential immune escape mechanism among immune subtypes. In addition, we constructed a transcriptional trajectory to visualize the distribution of individual patient. RESULTS: Our analysis identified and validated five reproducible immune subtypes with distinct cellular and molecular characteristics, potential immune escape mechanisms, genomic drivers, as well as clinical outcomes. An immune-cold subtype, with the least amount of lymphocyte infiltration, had a poorer prognosis. By contrast, an immune-hot subtype, which demonstrated the highest infiltration of CD8+ T cells, DCs and NK cells, and elevated IFN-γ response, had a comparatively favorable prognosis. Other subtypes showed more diverse gene expression and immune infiltration patterns with distinct clinical outcomes. Finally, our analysis revealed a complex immune landscape consisting of both discrete cluster and continuous spectrum. CONCLUSION: Overall, this study revealed five heterogeneous immune subtypes among ER+/PR–/HER2− breast cancer, also provided important implications for clinical translations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-03076-x. BioMed Central 2021-09-20 /pmc/articles/PMC8454077/ /pubmed/34544424 http://dx.doi.org/10.1186/s12967-021-03076-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Xie, Peiling An, Rui Yu, Shibo He, Jianjun Zhang, Huimin A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape |
title | A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape |
title_full | A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape |
title_fullStr | A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape |
title_full_unstemmed | A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape |
title_short | A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape |
title_sort | novel immune subtype classification of er-positive, pr-negative and her2-negative breast cancer based on the genomic and transcriptomic landscape |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454077/ https://www.ncbi.nlm.nih.gov/pubmed/34544424 http://dx.doi.org/10.1186/s12967-021-03076-x |
work_keys_str_mv | AT xiepeiling anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT anrui anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT yushibo anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT hejianjun anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT zhanghuimin anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT xiepeiling novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT anrui novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT yushibo novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT hejianjun novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape AT zhanghuimin novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape |